MMRSA Guide
Microscopic illustration of MRSA (Staphylococcus aureus) bacteria
Reference · Symptoms · MSSA vs MRSA

MSSA vs MRSA: what's the difference?

MSSA and MRSA are the same bacterium — Staphylococcus aureus. The difference is one letter and one gene: MRSA carries the mecA gene and is resistant to methicillin and most related antibiotics. MSSA is not. Symptoms look identical; treatment does not.

Written by David Roberts, editor · Updated

Checked against current CDC and IDSA guidance. Not medically reviewed. How we source this

The short answer

MSSA is methicillin-sensitive Staphylococcus aureus. MRSA is methicillin-resistant Staphylococcus aureus. Both cause the same spectrum of illness — from a boil on the leg to bloodstream infection, endocarditis, pneumonia, and sepsis. What separates them is which antibiotics still work. That single fact drives every practical decision, from which drug the pharmacy sends to the ward to whether a patient goes into contact isolation.

At a glance

AttributeMSSAMRSA
Full nameMethicillin-sensitive Staphylococcus aureusMethicillin-resistant Staphylococcus aureus
Antibiotic resistanceSensitive to standard beta-lactamsResistant to methicillin and most beta-lactams
First-line treatmentNafcillin, oxacillin, cefazolin, dicloxacillinVancomycin, daptomycin, linezolid; oral: doxycycline, clindamycin, Bactrim
Typical settingsCommunity and hospitalCommunity (CA-MRSA) and healthcare (HA-MRSA)
ContagiousnessSpreads by skin contact and shared itemsSame routes, similar transmissibility
Nasal carriage~30% of healthy people~2% of healthy people
Bacteraemia mortality~15–20% with appropriate therapy~20–25% with appropriate therapy
DiagnosisCulture + susceptibility, or PCRCulture + susceptibility, or PCR (mecA/mecC)

Are the symptoms different?

No. Clinically, MSSA and MRSA look the same. A skin abscess caused by MSSA and one caused by MRSA present with the same redness, swelling, warmth, and pus. Invasive syndromes — bacteraemia, endocarditis, pneumonia, osteomyelitis — produce the same fevers, rigors, and organ failure regardless of resistance status. You cannot look at an infection and tell which one it is.

Diagnosis therefore rests on the laboratory. A swab, blood culture, or tissue sample is grown on agar; the isolate is then tested against oxacillin (a methicillin surrogate) or checked by PCR for the mecA or mecC gene. The report comes back as MSSA or MRSA and treatment is adjusted accordingly.

Treatment differences

MSSA is easier to treat. For serious infection, IV nafcillin, oxacillin, or cefazolin are first-line — they penetrate tissues well, kill quickly, and have decades of outcome data behind them. Skin MSSA is treated with oral dicloxacillin or cephalexin.

MRSA does not respond to any of those drugs. Serious MRSA is treated with IV vancomycin, daptomycin, linezolid, or ceftaroline; skin MRSA is typically treated with oral doxycycline, clindamycin, or trimethoprim-sulfamethoxazole (Bactrim). Empiric therapy in a seriously ill patient usually covers MRSA from the start — the antibiotic is narrowed down to a beta-lactam only after cultures confirm MSSA. More information on our Treatment page →

Why the distinction matters

The choice of drug changes outcomes. In S. aureus bacteraemia, MSSA patients treated with a beta-lactam do better than MSSA patients treated with vancomycin — vancomycin is a good MRSA drug but a mediocre MSSA drug, and time on the wrong agent costs survival. Rapid PCR testing of blood cultures has become standard in many hospitals partly to shorten the window before therapy is right-sized.

Resistance also has downstream consequences: MRSA carriage triggers contact precautions in most healthcare settings, extends hospital stays, and complicates surgical planning. MSSA carriage does not.

Where each is found

MSSA is ubiquitous — about 30% of healthy people carry S. aureus in the anterior nares, and the great majority of those isolates are methicillin-sensitive. MRSA carriage is much rarer in the general population (around 2%) but is concentrated in specific groups: people recently hospitalised, dialysis patients, IV drug users, nursing-home residents, athletes in close-contact sports, and military recruits. Community-associated MRSA (CA-MRSA) has changed the picture over the last twenty years: many MRSA skin infections now arise in people with none of the traditional healthcare risk factors. Read more about the bacterium and how it spreads.

Related

Frequently asked questions

Is MSSA more or less dangerous than MRSA?
MSSA and MRSA cause the same range of infections — from small skin abscesses to bloodstream infection, endocarditis, and pneumonia — and both can kill. The difference is treatment: MSSA responds to standard beta-lactam antibiotics (nafcillin, oxacillin, cefazolin), which are more effective and less toxic than the MRSA alternatives. For bloodstream infection in particular, MSSA treated with a beta-lactam has better outcomes than MRSA treated with vancomycin.
Can MSSA turn into MRSA?
Not usually inside one person during one infection. MRSA arises when a strain of S. aureus acquires the mecA (or mecC) gene, which is carried on a mobile genetic element called SCCmec. That transfer happens at the population level over time — it is not something that flips during a course of antibiotics. What can happen is that a person colonised with MSSA acquires a separate MRSA strain from a healthcare setting or another person.
How do doctors tell MSSA from MRSA?
You cannot tell them apart by looking at the infection. Diagnosis requires a laboratory culture from the wound, blood, sputum, or nose, followed by antibiotic susceptibility testing (or a rapid PCR test for the mecA/mecC gene). The result — sensitive or resistant to methicillin/oxacillin — determines which antibiotic is used.
Is MSSA contagious like MRSA?
Yes. MSSA spreads the same way MRSA does — skin-to-skin contact, shared items such as towels or razors, and contaminated surfaces. Roughly 30% of healthy people carry S. aureus (mostly MSSA) in the nose without symptoms. The precautions are the same: cover wounds, wash hands, and do not share personal items.
What antibiotics treat MSSA vs MRSA?
MSSA is treated with beta-lactam antibiotics: IV nafcillin, oxacillin, or cefazolin for serious infection, and oral dicloxacillin or cephalexin for skin infection. MRSA does not respond to those drugs. Serious MRSA is treated with IV vancomycin, daptomycin, linezolid, or ceftaroline; skin MRSA is typically treated with oral doxycycline, clindamycin, or trimethoprim-sulfamethoxazole (Bactrim).
Which is more common, MSSA or MRSA?
MSSA is more common overall. Around 30% of the general population carries S. aureus in the nose, and only about 2% carries MRSA specifically. In US hospitals, roughly 40–50% of S. aureus bloodstream isolates are MRSA — the ratio depends heavily on the setting, the country, and the patient population.
Is MSSA a superbug?
MSSA is not usually classed as a superbug because it responds to standard antibiotics. It is still a serious pathogen — MSSA bacteraemia carries a mortality of around 15–20% — but the term superbug is generally reserved for organisms resistant to multiple first-line drugs, of which MRSA is the archetype.
References
  1. CDC. MRSA: clinical overview (2024)
  2. IDSA. Clinical practice guidelines for MRSA infections (2011)
  3. BMJ Best Practice. MRSA infection (2024)